IP Library Granted Patent US 10,010,620
Granted Patent B2
US 10,010,620 · App. 15/058,955 · Granted Jul 3, 2018

Tamper-resistant pharmaceutical dosage forms and process for making same

Inventors: Isaac Ghebre-Sellassie (Morris Plains, NJ); Hibreniguss Terefe (Piscataway, NJ)
Assignee: ExxPharma Therapeutics LLC
A61K47/48184A61K9/2009A61K9/2054A61K9/2077A61K31/138A61K31/485A61K47/58A61K47/585B01F7/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,010,620
App. No.
15/058,955
Granted
Jul 3, 2018
Kind
B2
Abstract

A process for the preparation of an erodible tamper-resistant dosage form that comprises a therapeutic agent-substrate complex embedded in a thermo-formable matrix, such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive. The dosage form provides resistance to intentional or unintentional tampering such as chewing, crushing and grinding, and volatilization.

Claims (12)

1. A process of preparing an erodible tamper-resistant dosage form, comprising the steps of:

(1) blending at least one therapeutic agent and at least one substrate in a therapeutic agent-to-substrate ratio from 1:20 to 20:1 by weight;

(2) reacting the at least one therapeutic agent and the at least one substrate to form a therapeutic agent-substrate complex using a twin-screw extruder;

(3) forming a thermo-formable matrix blend with at least one thermoplastic polymer and at least one pharmaceutical additive;

(4) mixing the therapeutic agent-substrate complex and the thermo-formable matrix blend in a ratio from 1:20 to 20:1 by weight;

(5) granulating the therapeutic agent-substrate complex and the thermo-formable matrix blend to form the erodible tamper-resistant dosage form in which the therapeutic agent-substrate complex is embedded in the thermo-formable matrix;

(6) shaping the tamper-resistant dosage form into one of an immediate release or modified release tablet form and an immediate release or modified release multiparticulate form; and

(7) optionally, film-coating one of the tablet form and the multiparticulate form.

2. The process of claim 1 , wherein the reacting step of (2) is carried out by a reactive extrusion process.

3. The process of claim 1 , wherein the granulating step of (5) is carried out by a hot melt extrusion process.

4. The process of claim 1 , wherein the granulating step of (5) is carried out by a wet granulation process.

5. The process of claim 1 , wherein the granulating step of (5) is carried out by a dry granulation process.

Assignments (3)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 26, 2026
From: NEUROCRINE BIOSCIENCES, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 075670/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2020
From: EXXPHARMA THERAPEUTICS LLC
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 054687/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2016
From: GHEBRE-SELLASSIE, ISAAC; TEREFE, HIBRENIGUSS
To: EXXPHARMA THERAPEUTICS LLC
Reel/Frame 037912/0428 →
Continuity (2)
Continuation PCTUS2014053758 · Sep 2, 2014
Related Publication 20160175454A1 · Jun 23, 2016